Clinical Trial Update: Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a Tick-Borne Encephalitis vaccine in healthy Japanese participants aged 1 year and older has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tick-borne Encephalitis

Drugs mentioned

• Pfizer Tick-Borne Encephalitis vaccine (unofficial name; sponsor-listed)

Snippet

Sponsor: Pfizer | Conditions: Tick-Borne Encephalitis | Phase 3 | Status: COMPLETED | Results posted: 2023-11-22